A Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection

Annals of Hepatology

Volumn 12, Issue 2, 2013, Pages 282-293

  Yoshida, Eric M ^a   Lilly, Leslie B ^b   Marotta, Paul J ^c   Mason, Andrew L ^d   Bilodeau, Marc ^e   Vaillancourt, Marc ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d University of Edmonton   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

^f Novartis Pharma Canada Inc   (Canada)

Author keywords

Liver transplant; Retrospective study; Tacrolimus

Indexed keywords

CYCLOSPORIN; INTERFERON; PEGINTERFERON; RIBAVIRIN; TACROLIMUS; ANTIVIRUS AGENT; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; VIRUS RNA;

ACUTE GRAFT REJECTION; ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; CANADA; CHOLESTATIC HEPATITIS; CHRONIC GRAFT REJECTION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DONOR; DONOR AGE; FEMALE; FIBROSING CHOLESTATIC HEPATITIS; FIBROSIS; GENOTYPE; GRAFT FAILURE; GRAFT FIBROSIS; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT DURATION; VIROLOGY; BLOOD; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; GENETICS; GRAFT REJECTION; HEPATITIS C VIRUS; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; RISK; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CANADA; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CYCLOSPORINE; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84885669723     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31367-5     Document Type: Article

References (24)

1. Belle SH, Beringer KC, Detre KM. Recent findings concerning liver transplantation in the United States. In: Terasaki PI, Cecka JM (eds.). Clinical Transplants 1996. Los Angeles: UCLA Tissue Typing Laboratory; 1996, p. 15-29.
2. O'Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008: 1764.
3. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detre K, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823.
4. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
5. Satapathy SK, Sclair S, Fiel MI, Del Rio Martin J, Schiano T. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res 2011; 4: 328-39.
6. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, Córdoba J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673.
7. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, et al. Suppression of hepatitis C virus replication by cyclosporine A is mediated by blockade of cyclophillins. Gastroenterology 2005; 129: 1031.
8. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, Cabrera R, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virologic response after liver transplantation. Liver Transp 2006; 12: 19.
9. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C. Impact of tacrolimus vs. Cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective randomized study. Liver Transp 2004; 10: 1258.
10. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Effect of calcineurin inhibitors on survival and histologic disease severity in hepatitis C infected liver transplant recipients. Liver Transp 2006; 12: 762.
11. Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, Bain V, et al. Early steroid withdrawal alters liver transplantation: the Canadian tacrolimus vs. cyclosporine A trial: 1 year follow-up. Liver Transp 2003; 9: 587.
12. Hoitsma AJ, Hilbrands LB. Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression. Clin Transplant 2006; 20(5): 659.
13. Cho YM, Park KS, Jung HS, Jeon HJ, Ahn C, Ha J, Kim SJ, et al. High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allograft recipients according to American Diabetes Association criteria. Diabetes Care 2003; 26: 1123.
14. Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 2009; 54: 2699.
15. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2B plus ribavirinin patients with chronic hepatitis C. Hepatology 2003; 38: 645.
16. Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782.
17. Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, Girgrah N, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88: 1214.
18. Hirano K, Ichikawa T, Nakao K, Matsumoto A, Miyaaki H, Shibata H, Eguchi S, et al. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferoninduced antiviral protein in human hepatocyte cells. Liver Transpl 2008; 14: 292.
19. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282.
20. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003; 38: 567.
21. Watashi K. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection. Curr Opin Investig Drugs 2010; 11: 213.
22. Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, Moya A, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202.
23. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248.
24. ReViS-TC Study Group. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011; 92: 334.